87E.F Dianthus Therapeutics, Inc.

Healthcare Biotechnology Frankfurt Exchange
78.50 EUR
Close of Nov 12, 2026
31.20 99.50
Market cap
EUR 4.42B
P/E
-
P/B
4.02x
ROE
-14.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 87E.F undervalued?

Graham number

The Graham number of Dianthus Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Dianthus Therapeutics, Inc. fundamental analysis

No fundamental analysis for Dianthus Therapeutics, Inc. yet.

Dianthus Therapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production…

Full company profile